Cover Image
市場調查報告書

化膿性汗腺炎 : 開發平台分析

Hidradenitis Suppurativa - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229796
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
化膿性汗腺炎 : 開發平台分析 Hidradenitis Suppurativa - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 63 Pages
簡介

化膿性汗腺炎,是所謂皮膚下出現粒狀或小石狀朣包等慢性皮膚疾病。尤其常發於皮膚容易產生摩擦的地方(腋下、鼠鼷部、臀部之間、乳房下方等)會頑強地頻發朣包,為其特徵。

本報告提供全球各國治療化膿性汗腺炎用的開發中產品開發情形相關分析、彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)進展狀況)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

化膿性汗腺炎概要

化膿性汗腺炎的開發

  • 化膿性汗腺炎開發中產品:概要
  • 化膿性汗腺炎開發中產品:比較分析

各企業開發中的化膿性汗腺炎治療藥

大學/研究機關研究中的化膿性汗腺炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

化膿性汗腺炎治療藥:開發中的產品一覽(各企業)

化膿性汗腺炎治療藥:研究中的產品一覽(大學/研究機關)

化膿性汗腺炎開發治療藥的企業

  • AbbVie Inc.
  • Cellceutix Corporation
  • Delenex Therapeutics AG
  • Johnson & Johnson
  • Novartis AG

化膿性汗腺炎:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • adalimumab
  • adalimumab 生技仿製藥
  • CJM-112
  • DLX-105
  • DLX-2751
  • 化膿性汗腺炎細胞薄膜破壞小分子
  • ustekinumab

化膿性汗腺炎治療藥:最新的藥物簡介

暫停中的計劃

開發中止的產品

化膿性汗腺炎相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8225IDB

Summary

Global Markets Direct's, 'Hidradenitis Suppurativa - Pipeline Review, H2 2016', provides an overview of the Hidradenitis Suppurativa pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa
  • The report reviews pipeline therapeutics for Hidradenitis Suppurativa by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hidradenitis Suppurativa therapeutics and enlists all their major and minor projects
  • The report assesses Hidradenitis Suppurativa therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hidradenitis Suppurativa
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hidradenitis Suppurativa Overview
  • Therapeutics Development
    • Pipeline Products for Hidradenitis Suppurativa - Overview
  • Hidradenitis Suppurativa - Therapeutics under Development by Companies
  • Hidradenitis Suppurativa - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hidradenitis Suppurativa - Products under Development by Companies
  • Hidradenitis Suppurativa - Companies Involved in Therapeutics Development
    • Cellceutix Corporation
    • Celtaxsys, Inc.
    • Delenex Therapeutics AG
    • Johnson & Johnson
    • Novartis AG
    • Sandoz International GmbH
  • Hidradenitis Suppurativa - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acebilustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJM-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2751 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ustekinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Xilonix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hidradenitis Suppurativa - Dormant Projects
  • Hidradenitis Suppurativa - Discontinued Products
  • Hidradenitis Suppurativa - Product Development Milestones
    • Featured News & Press Releases
      • Sep 11, 2014: Delenex Announces New Clinical Data
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hidradenitis Suppurativa, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Hidradenitis Suppurativa - Pipeline by Cellceutix Corporation, H2 2016
  • Hidradenitis Suppurativa - Pipeline by Celtaxsys, Inc., H2 2016
  • Hidradenitis Suppurativa - Pipeline by Delenex Therapeutics AG, H2 2016
  • Hidradenitis Suppurativa - Pipeline by Johnson & Johnson, H2 2016
  • Hidradenitis Suppurativa - Pipeline by Novartis AG, H2 2016
  • Hidradenitis Suppurativa - Pipeline by Sandoz International GmbH, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hidradenitis Suppurativa - Dormant Projects, H2 2016
  • Hidradenitis Suppurativa - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hidradenitis Suppurativa, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top